Compare GSK plc (GSK) vs Kyndryl Holdings Inc (KD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Kyndryl Holdings Inc — how do they compare? GSK plc trades at $50.3 (market cap $102.60B), while Kyndryl Holdings Inc trades at $12.78 (market cap $2.91B). The key difference: GSK plc is far larger — about 35.3× Kyndryl Holdings Inc's market cap, and GSK plc pays a 3.57% dividend while Kyndryl Holdings Inc pays none. Which is the better fit depends on your goals.
| GSK | KD | |
|---|---|---|
Market Cap | $102.60B | $2.91B |
Sector | Health | Technology |
52-Week High | $61.18 | $33.14 |
52-Week Low | $38.22 | $10.59 |
Enterprise Value | $123.04B | $5.74B |
Dividend Yield | 3.57% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.16, down 1.51% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 earnings of $1.36 per share, beating estimates, and announced a $2.52 billion cost-saving plan to accelerate drug development. Revenue growth remains steady, with 2025 revenue at $32.67 billion and net income of $5.72 billion, though profit margins have fluctuated in recent years.
Outlook is positive with continued earnings beats and strategic investments, but risks include competitive pressures and regulatory uncertainties. Analyst sentiment is mixed with 31% buy ratings, 55% hold, and 14% sell, reflecting cautious optimism amid execution risks and market volatility.
Kyndryl (KD) trades at $13.63, down 2.78% today, with a mixed technical picture showing bullish moving averages but neutral oscillators. Fundamentally, the company shows improving profitability with 2025 net income of $252M after years of losses, though recent Q1 2027 earnings missed expectations. The acquisition of Healthcare IT Leaders and new AI services demonstrate strategic growth initiatives.
While analyst consensus leans Hold (71%) with a $13.50 price target near current levels, improving cash flow and debt management provide stability. Key risks include revenue declines, ongoing investigations, and competitive pressures in IT services. The stock presents a turnaround story with moderate upside potential balanced by execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Kyndryl Holdings Inc
Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives.
Read more on KD →
